2025
Impact of PARP Inhibitors on Health-related Quality of Life in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis
Roessler N, Miszczyk M, Matsukawa A, Dematteis A, Alfarhan A, Cormio A, Alqahtani A, Rajwa P, Schuettfort V, Vetterlein M, Soeterik T, Fazekas T, Fisch M, Leapman M, Karakiewicz P, Shariat S. Impact of PARP Inhibitors on Health-related Quality of Life in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Open Science 2025, 80: 48-56. PMID: 40994543, PMCID: PMC12454867, DOI: 10.1016/j.euros.2025.08.008.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerFunctional Assessment of Cancer Therapy-ProstateImpact of PARP inhibitorsCastration-resistant prostate cancerPARP inhibitorsProspective trialsProstate cancerHealth-related quality of lifeHealth-related qualityQuality of lifeFunctional Assessment of Cancer Therapy-Prostate total scoreMeta-analysisHigh riskMean differenceAdvanced prostate cancerPARP inhibitor treatmentClinically meaningful deteriorationClinically meaningful impactTime pointsFunctional assessmentHigh risk of biasSystematic reviewStandard of careClinically Meaningful ImprovementsLate time points
2022
Clinical actionability and utilization of next-generation sequencing for prostate cancer in a changing treatment landscape
Griffin J, Tsao C, Patel V, Liaw B, Guin S, Joshi H, Rossi M, Hantash F, Zhou X, Tewari A, Galsky M, Oh W, Chen R, Jun T. Clinical actionability and utilization of next-generation sequencing for prostate cancer in a changing treatment landscape. Frontiers In Urology 2022, 2: 997396. DOI: 10.3389/fruro.2022.997396.Peer-Reviewed Original ResearchMetastatic prostate cancerProstate cancerNGS testingNext-generation sequencingStudy periodLater-line treatmentSingle-center cohortDays of diagnosisPoly (ADP-ribose) polymerase (PARP) inhibitorsElectronic medical recordsPARP inhibitor treatmentMetastatic diseasePrior linesSystemic therapyTreatment landscapeMedian timeMetastatic diagnosisRetrospective studyMedical recordsMedian numberClinical actionabilityNext treatmentPatientsInhibitor treatmentNGS findings688P Transcriptional profile changes in matched paired tumor samples after PARP inhibitor treatment in head and neck squamous cell carcinoma (HNSCC)
Moutafi M, Economopoulou P, Kotsantis I, Anastasiou M, Foukas P, Fountzilas G, Rimm D, Psyrri A. 688P Transcriptional profile changes in matched paired tumor samples after PARP inhibitor treatment in head and neck squamous cell carcinoma (HNSCC). Annals Of Oncology 2022, 33: s857-s858. DOI: 10.1016/j.annonc.2022.07.812.Peer-Reviewed Original Research
2021
CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).
Pachynski R, Retz M, Goh J, Burotto M, Gravis G, Castellano D, Flechon A, Zschaebitz S, Shaffer D, Limon J, Grimm M, McCune S, Amin N, Li J, Wang X, Unsal-Kacmaz K, Saad F, Petrylak D, Fizazi K. CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2021, 39: 5044-5044. DOI: 10.1200/jco.2021.39.15_suppl.5044.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerTreatment-related AEsObjective response rateRadiographic progression-free survivalCohorts A1Overall survivalDisease progression/unacceptable toxicityProstate-specific antigen (PSA) response rateResponse rateProgression/unacceptable toxicityCastration-resistant prostate cancerNovel hormonal therapiesSecondary efficacy resultsProgression-free survivalNew safety signalsPhase 2 trialPD-L1 upregulationPlausible therapeutic strategyPARP inhibitor treatmentMeasurable diseaseVisceral metastasesHormonal therapySecondary endpointsUnacceptable toxicityEvaluable tumors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply